# US 2026/0217649 A1 · Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0217649 A1
- Document ID: US20260217649A1
- Status: Published application
- Kind: A1
- Application number: 19/638,269
- Filed: 2026-04-03
- Published: 2026-07-30
- Earliest claimed: 2022-01-06
- Assignees: Terran Biosciences Inc.
- Applicants: Terran Biosciences Inc.
- Inventors: Samuel CLARK
- Web page: https://patentgrep.com/patent/US20260217649A1

## CPC

- C07D 209/16: Tryptamines
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/32: Alcohol-abuse
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate (4-OH-DIPT), e.g., 4-OH-DIPT hemi-glutarate, 4-OH-DIPT hemi-succinate, 4-OH-DIPT hemi-succinate hydrochloride, and 4-OH-DIPT hemi-glutarate hydrochloride. The solid form may be a salt and/or a crystalline form of the 4-OH-DIPT, such as a polymorph of 4-OH-DIPT or a salt thereof. Also disclosed are methods for making the solid forms and methods for administering the solid forms. The disclosed solid forms of 4-OH-DIPT are useful for treating neurological disease and/or a psychiatric disorder in a subject.

## Claims

### Claim 1

A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to a subject an effective amount of a crystalline solid form of 4-OH-DIPT hemi-glutarate hydrochloride characterized by having two or more X-ray powder diffraction peaks at diffraction angles 2θ(°) selected from the group consisting of 18.4±0.2, 23.3±0.2, and 24.9±0.2, as measured by X-ray diffractometry by irradiation with Cu-Kα X-rays.

### Claim 2 (depends on 1)

The method of claim 1, wherein the crystalline solid form of 4-OH-DIPT hemi-glutarate hydrochloride is characterized by having XRPD peaks at diffraction angles 2θ(°) 18.4±0.2, 23.3±0.2, and 24.9±0.2, as measured by X-ray diffractometry by irradiation with Cu-Kα X-rays.

### Claim 3 (depends on 1)

The method of claim 1, wherein the crystalline solid form of 4-OH-DIPT hemi-glutarate hydrochloride is characterized by having two or more XRPD peaks at diffraction angles 2θ(°) selected from the group consisting of 18.4±0.2, 23.3±0.2, 24.9±0.2, 24.3±0.2, and 15.9±0.2, as measured by X-ray diffractometry by irradiation with Cu-Kα X-rays.

### Claim 4 (depends on 1)

The method of claim 1, wherein the crystalline solid form of 4-OH-DIPT hemi-glutarate hydrochloride is characterized by having two or more XRPD peaks at diffraction angles 2θ(°) selected from the group consisting of 18.4±0.2, 23.3±0.2, 24.9±0.2, 24.3±0.2, 15.9±0.2, 20.0±0.2, and 26.6±0.2, as measured by X-ray diffractometry by irradiation with Cu-Kα X-rays.

### Claim 5 (depends on 1)

The method of claim 1, wherein the crystalline solid form of 4-OH-DIPT hemi-glutarate hydrochloride is characterized by having two or more XRPD peaks at diffraction angles 2θ(°) selected from the group consisting of 18.4±0.2, 23.3±0.2, 24.9±0.2, 24.3±0.2, 15.9±0.2, 20.0±0.2, 26.6±0.2, 15.0±0.2, 28.3±0.2, and 21.8±0.2, as measured by X-ray diffractometry by irradiation with Cu-Kα X-rays.

### Claim 6 (depends on 1)

The method of claim 1, wherein the crystalline solid form of 4-OH-DIPT hemi-glutarate hydrochloride is characterized by having two or more XRPD peaks at diffraction angles 2θ(°) selected from the group consisting of 7.4±0.2, 9.0±0.2, 12.4±0.2, 12.9±0.2, 15.0±0.2, 15.9±0.2, 18.4±0.2, 19.2±0.2, 20.0±0.2, 21.8±0.2, 23.3±0.2, 24.3±0.2, 24.9±0.2, 26.6±0.2, 28.3±0.2, 29.2±0.2, 33.0±0.2, 34.2±0.2, and 36.3±0.2, as measured by X-ray diffractometry by irradiation with Cu-Kα X-rays.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has a neurological disease or a psychiatric disorder.

### Claim 8 (depends on 7)

The method of claim 7, wherein the neurological disorder is a neurodegenerative disorder.

### Claim 9 (depends on 7)

The method of claim 7, wherein the neurological disorder or psychiatric disorder is depression, addiction, anxiety, or a post-traumatic stress disorder.

### Claim 10 (depends on 7)

The method of claim 7, wherein the neurological disorder or psychiatric disorder is treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder.

### Claim 11 (depends on 7)

The method of claim 7, wherein the neurological disorder or psychiatric disorder is stroke, traumatic brain injury, or a combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject has a disease of women's reproductive health.

### Claim 13 (depends on 12)

The method of claim 12, wherein the disease of women's reproductive health is post-partum depression.

### Claim 14 (depends on 1)

The method of claim 1, wherein the administering comprises oral, parenteral, topical administration.

### Claim 15 (depends on 14)

The method of claim 14, wherein the administering is oral administration.

### Claim 16 (depends on 1)

The method of claim 1, wherein the administering comprises administering by injection, inhalation, intranasal, intramuscular, subcutaneous, intravenous, intrathecal, intraocular, intravaginal, intrarectal, or transdermal routes.

### Claim 17 (depends on 16)

The method of claim 16, wherein the administering is subcutaneous administration.
